Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 2Sarcoma, Myeloid 1Sarcoma 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Dexrazoxane × 30 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡